Zhejiang Yatai Pharmaceutical Co Ltd (002370) - Net Assets
Based on the latest financial reports, Zhejiang Yatai Pharmaceutical Co Ltd (002370) has net assets worth CN¥1.12 Billion CNY (≈ $164.06 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.21 Billion ≈ $177.64 Million USD) and total liabilities (CN¥92.77 Million ≈ $13.58 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 002370 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.12 Billion |
| % of Total Assets | 92.36% |
| Annual Growth Rate | 11.16% |
| 5-Year Change | 47.21% |
| 10-Year Change | 22.57% |
| Growth Volatility | 68.45 |
Zhejiang Yatai Pharmaceutical Co Ltd - Net Assets Trend (2006–2024)
This chart illustrates how Zhejiang Yatai Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Zhejiang Yatai Pharmaceutical Co Ltd total assets for the complete picture of this company's asset base.
Annual Net Assets for Zhejiang Yatai Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual net assets of Zhejiang Yatai Pharmaceutical Co Ltd from 2006 to 2024. For live valuation and market cap data, see 002370 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥972.18 Million ≈ $142.26 Million |
+67.37% |
| 2023-12-31 | CN¥580.87 Million ≈ $85.00 Million |
+92.84% |
| 2022-12-31 | CN¥301.22 Million ≈ $44.08 Million |
-30.43% |
| 2021-12-31 | CN¥432.96 Million ≈ $63.36 Million |
-34.44% |
| 2020-12-31 | CN¥660.41 Million ≈ $96.64 Million |
+4.32% |
| 2019-12-31 | CN¥633.06 Million ≈ $92.64 Million |
-73.36% |
| 2018-12-31 | CN¥2.38 Billion ≈ $347.71 Million |
+4.30% |
| 2017-12-31 | CN¥2.28 Billion ≈ $333.36 Million |
+5.15% |
| 2016-12-31 | CN¥2.17 Billion ≈ $317.02 Million |
+173.14% |
| 2015-12-31 | CN¥793.15 Million ≈ $116.06 Million |
+6.13% |
| 2014-12-31 | CN¥747.31 Million ≈ $109.36 Million |
+5.28% |
| 2013-12-31 | CN¥709.83 Million ≈ $103.87 Million |
+0.84% |
| 2012-12-31 | CN¥703.94 Million ≈ $103.01 Million |
-5.55% |
| 2011-12-31 | CN¥745.30 Million ≈ $109.06 Million |
+3.52% |
| 2010-12-31 | CN¥719.95 Million ≈ $105.35 Million |
+213.31% |
| 2009-12-31 | CN¥229.79 Million ≈ $33.63 Million |
+15.65% |
| 2008-12-31 | CN¥198.69 Million ≈ $29.07 Million |
+25.81% |
| 2007-12-31 | CN¥157.93 Million ≈ $23.11 Million |
+9.08% |
| 2006-12-31 | CN¥144.78 Million ≈ $21.19 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Yatai Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3032.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥728.59 Million | 74.94% |
| Other Comprehensive Income | CN¥132.52 Million | 13.63% |
| Other Components | CN¥1.90 Billion | 195.27% |
| Total Equity | CN¥972.18 Million | 100.00% |
Zhejiang Yatai Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Yatai Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Odfjell SE
OL:ODF
|
$734.39 Million |
|
Hallador Energy Company
NASDAQ:HNRG
|
$734.44 Million |
|
Nexpoint Residential Trust Inc
NYSE:NXRT
|
$734.89 Million |
|
Platzer Fastigheter Holding AB (publ)
ST:PLAZ-B
|
$734.90 Million |
|
Gujarat State Fertilizers & Chemicals Limited
NSE:GSFC
|
$734.28 Million |
|
Southern Cross Electrical Engineering Ltd
AU:SXE
|
$733.95 Million |
|
Stratasys Ltd
NASDAQ:SSYS
|
$733.90 Million |
|
Santacruz Silver Mining Ltd. Common Shares
NASDAQ:SCZM
|
$733.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Yatai Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 580,874,409 to 972,181,003, a change of 391,306,594 (67.4%).
- Net income of 34,239,781 contributed positively to equity growth.
- Dividend payments of 11,901,762 reduced retained earnings.
- Other comprehensive income increased equity by 132,521,363.
- Other factors increased equity by 236,447,212.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥34.24 Million | +3.52% |
| Dividends Paid | CN¥11.90 Million | -1.22% |
| Other Comprehensive Income | CN¥132.52 Million | +13.63% |
| Other Changes | CN¥236.45 Million | +24.32% |
| Total Change | CN¥- | 67.37% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Yatai Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.74x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 14.74x to 4.74x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CN¥0.46 | CN¥6.73 | x |
| 2007-12-31 | CN¥0.51 | CN¥6.73 | x |
| 2008-12-31 | CN¥0.65 | CN¥6.73 | x |
| 2009-12-31 | CN¥0.76 | CN¥6.73 | x |
| 2010-12-31 | CN¥1.88 | CN¥6.73 | x |
| 2011-12-31 | CN¥1.79 | CN¥6.73 | x |
| 2012-12-31 | CN¥1.78 | CN¥6.73 | x |
| 2013-12-31 | CN¥1.94 | CN¥6.73 | x |
| 2014-12-31 | CN¥1.84 | CN¥6.73 | x |
| 2015-12-31 | CN¥1.91 | CN¥6.73 | x |
| 2016-12-31 | CN¥4.90 | CN¥6.73 | x |
| 2017-12-31 | CN¥4.23 | CN¥6.73 | x |
| 2018-12-31 | CN¥4.39 | CN¥6.73 | x |
| 2019-12-31 | CN¥1.18 | CN¥6.73 | x |
| 2020-12-31 | CN¥1.23 | CN¥6.73 | x |
| 2021-12-31 | CN¥0.81 | CN¥6.73 | x |
| 2022-12-31 | CN¥0.56 | CN¥6.73 | x |
| 2023-12-31 | CN¥0.98 | CN¥6.73 | x |
| 2024-12-31 | CN¥1.42 | CN¥6.73 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Yatai Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.45%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.44x
- Recent ROE (3.52%) is above the historical average (-14.43%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 15.46% | 7.78% | 0.86x | 2.32x | CN¥7.58 Million |
| 2007 | 24.75% | 11.41% | 0.95x | 2.29x | CN¥23.29 Million |
| 2008 | 20.94% | 10.02% | 1.01x | 2.06x | CN¥21.74 Million |
| 2009 | 20.95% | 11.21% | 0.97x | 1.92x | CN¥25.17 Million |
| 2010 | 5.84% | 9.66% | 0.50x | 1.20x | CN¥-29.95 Million |
| 2011 | 5.88% | 10.42% | 0.48x | 1.17x | CN¥-30.74 Million |
| 2012 | -3.65% | -8.14% | 0.39x | 1.16x | CN¥-96.11 Million |
| 2013 | 0.77% | 1.75% | 0.39x | 1.13x | CN¥-65.50 Million |
| 2014 | 5.43% | 10.80% | 0.44x | 1.14x | CN¥-34.16 Million |
| 2015 | 7.06% | 11.98% | 0.22x | 2.62x | CN¥-23.08 Million |
| 2016 | 4.49% | 12.70% | 0.31x | 1.13x | CN¥-118.91 Million |
| 2017 | 6.15% | 15.38% | 0.32x | 1.26x | CN¥-87.29 Million |
| 2018 | 6.38% | 13.33% | 0.32x | 1.50x | CN¥-85.49 Million |
| 2019 | -303.49% | -270.87% | 0.31x | 3.58x | CN¥-1.98 Billion |
| 2020 | 4.13% | 5.30% | 0.26x | 2.96x | CN¥-38.77 Million |
| 2021 | -52.73% | -72.44% | 0.20x | 3.72x | CN¥-271.58 Million |
| 2022 | -44.06% | -35.54% | 0.25x | 5.06x | CN¥-162.84 Million |
| 2023 | -2.04% | -2.82% | 0.29x | 2.46x | CN¥-69.96 Million |
| 2024 | 3.52% | 8.45% | 0.29x | 1.44x | CN¥-62.98 Million |
Industry Comparison
This section compares Zhejiang Yatai Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,347,197,696
- Average return on equity (ROE) among peers: 4.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Yatai Pharmaceutical Co Ltd (002370) | CN¥1.12 Billion | 15.46% | 0.08x | $734.34 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $638.89 Million | 0.88% | 0.70x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.05 Billion | 10.46% | 0.19x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $994.58 Million | 2.01% | 2.11x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $332.48 Million | 26.89% | 0.68x | $3.30 Billion |
About Zhejiang Yatai Pharmaceutical Co Ltd
Zhejiang Yatai Pharmaceutical Co., Ltd. researches, produces, sells, and exports pharmaceutical products in China and internationally. The company offers solid dosage, cephalosporin powder injection, and freeze-dried powder injection products. It also provides various antibiotic and non-antibiotic drugs. The company was founded in 1989 and is based in Shaoxing, China.